Here are relevant reports on : pcr-thermocycler-market
-
Top 10 Cellular Analysis Market by Technology (Imaging, PCR, Flow Cytometry, High-content Screening, Blotting, Spectrophotometry), Application (Stem Cell, Cancer, Tissue Engineering) & End User (Biotechnology, Research) - Global Forecast to 2021
The top 10 cellular analysis market is expected to reach USD 41.34 Billion by 2021 from USD 28.66 Billion in 2016, at a CAGR of 7.6% during the forecast period. Cellular analysis is used for cell identification, cell interaction, cell viability, cell proliferation, cell structure study, cell signaling/cell transduction, target identification & validation, cell counting, and quality control. Currently, cellular analysis technologies are used in various phases of the drug discovery process, cancer diagnosis (oncology), blood cell analysis, toxicity testing, personalized medicine, pathogen testing, and other applications.
- Published: January 2017
- Price: $ 4950
- TOC Available:
-
Genotyping Assay Market by Product & Services (Kits, Instruments, Bioinformatics), Technology (PCR, Sequencing, Microarray), Application (Pharmacogenomics, Animal Genetics), End User (Pharma & Biotech Companies, Diagnostic Labs) & Region - Global Forecast to 2029
The global genotyping assay market, valued at US$17.4B in 2023, is forecasted to grow at a 13.8% CAGR, reaching US$19.4B by 2024 and US$37.1B by 2029. This growth is driven by advancements in DNA sequencing technology, rising prevalence of genetic disorders, and increased application in personalized medicine and drug development.
- Published: June 2024
- Price: $ 4950
- TOC Available:
-
Europe Epigenetics Market by Product & Service [Enzymes, Kits & Reagents (Antibodies), Software], Method [DNA Methylation, Histone Modification], Technique [NGS, PCR], Application [Oncology, Immunology, Developmental Biology], End User - Forecast to 2030
The Europe epigenetics market, valued at USD 0.57 billion in 2024, stood at USD 0.63 billion in 2025 and is projected to advance at a resilient CAGR of 14.1% from 2025 to 2030, culminating in a forecasted valuation of USD 1.22 billion by the end of the period. Growth is supported by a well-funded life sciences ecosystem, with rising oncology and precision medicine programs that increasingly rely on DNA methylation and chromatin profiling for biomarker discovery and translational research.
- Published: July 2026
- Price: $ 4950
- TOC Available:
-
Companion Diagnostics Market by Product (Assays, Kits, & Reagents, Instruments, Software), Technology (PCR, NGS, ISH, IHC), Indication (Breast, Lung, Colorectal Cancer, CVD, Infectious), Drug Class (MAB, Cell & Gene Therapy) - Global Forecast to 2031
The global companion diagnostics market is projected to reach USD 11.57 billion by 2031, growing at a CAGR of 12.9% during the forecast period (2026–2031). The report covers key segments, regional analysis, and competitive landscape across the market ecosystem.
- Published: June 2026
- Price: $ 4950
- TOC Available:
-
Breast Cancer Liquid Biopsy Market by Circulating Biomarkers, Region, End User, Investments, Market Dynamics, Platform Comparison (NGS, PCR), Competitive Landscape (Acquisition, Mergers, Collaboration, Competitive technology) & Geography
The global breast cancer liquid biopsy market is projected to grow at a CAGR of 23.1%. Factors such as increasing prevalence of breast cancer, increasing preference for noninvasive procedures, initiatives undertaken by government and global health organizations, technological advancements to augment market revenues, rising emphasis on personalized medicine in clinical practice, and increased funding for liquid biopsy R&D are driving the growth of the breast cancer liquid biopsy market. The key players in the global breast cancer liquid biopsy market are QIAGEN N.V. (Netherlands), Roche Diagnostics (US), Bio-Rad Laboratories Inc. (US), Myriad Genetics, Inc. (US), Menarini Silicon Biosystems (Italy), Genomic Health, Inc. (US), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Biocept, Inc. (US), Trovagene, Inc. (US), Guardant Health, Inc. (US), RainDance Technologies, Inc. (US), and MDx Health SA (US).
- Published: August 2018
- Price: $ 4950
- TOC Available:
-
Asia Pacific Epigenetics Market by Offering [Enzymes, Kits & Reagents, Software, Services], Method [DNA Methylation, Histone Modification], Technique [NGS, PCR], Application [Oncology, Immunology, Developmental Biology], End User - Forecast to 2030
The Asia Pacific epigenetics market, valued at US$0.44 billion in 2024, stood at US$0.49 billion in 2025 and is projected to advance at a resilient CAGR of 14.6% from 2025 to 2030, culminating in a forecasted valuation of US$0.97 billion by the end of the period. The Asia Pacific epigenetics market is experiencing growth, driven by increasing demand for precise biomarker discovery and multi-omics research across oncology, immunology, and precision medicine programs.
- Published: July 2026
- Price: $ 4950
- TOC Available:
-
Biomarker Technologies Market by Profiling Technology (Chromatography, NGS, PCR, Mass Spectrometry, Immunoassay, Liquid Biopsy (ddPCR, DHPLC)), Research Area (Proteomics, Lipidomics), Application (Biomarker Validation, Biomarker Discovery) & Geography
The global biomarker technologies market is projected to grow at a CAGR of 9.7%. The key players in the biomarker technologies market are Thermo Fisher Scientific (US), Agilent Technologies (US), Roche (Switzerland), Danaher Corporation (US), Waters Corporation (US), Shimadzu Corporation (Japan), and Bio-Rad Laboratories (US).
- Published: May 2018
- Price: $ 15000
- TOC Available:
-
Patient Blood Management Market by Product (Instrument (Centrifuge, Transfusion Device, Apheresis, PCR, NGS, Storage Device), Accessories (Syringes, Vials), Reagents, Software)), Component, End User (Blood Bank, Hospital) - Global Forecast to 2024
The global patient blood management market size is expected to grow USD 15.3 billion by 2024, at a CAGR of 7.4% during the forecasting period. The major players in the market include Haemonetics Corporation (US), Fresenius SE & Co. KGaA (Germany), Terumo Corporation (Japan), Immucor, Inc. (US), B. Braun Melsungen AG (Ireland), Macopharma (US), bioMérieux SA (France), Asahi Kasei Corporation (Japan), Bio-Rad Laboratories, Inc. (US), Abbott Laboratories (US), Grifols, S.A. (Spain), F. Hoffmann-La Roche LTD (Switzerland), LivaNova PLC (UK), Danaher Corporation (US), Mediware Information Systems (US), Kawasumi Laboratories, Inc. (Japan), Haier Biomedical (China), Diatron (Hungary), and BAG Diagnostics GmbH (Germany), among others.
- Published: December 2019
- Price: $ 4950
- TOC Available:
-
Hepatitis Testing Market / Diagnosis Market by Disease Type (Hepatitis B, Hepatitis C, Other Hepatitis), Technology (ELISA, RDT, PCR, INAAT), End User (Hospitals, Diagnostic Laboratories, Blood Banks), and Region - Global Forecast to 2026
The global hepatitis testing market growth is primed to transition from $2.8 billion in 2021 to $3.6 billion by 2026, showcasing a strong CAGR of 4.7%. The growth of the global market is being driven by factors such as the high burden of hepatitis, increasing blood transfusion and donations, benefits of POC instruments and kits, and awareness initiatives on hepatitis.
- Published: November 2021
- Price: $ 4950
- TOC Available:
-
Pharmacogenomics Market by Product & Service (Kits & Reagents), Technology (Sequencing, PCR, Microarray), Application (Drug Discovery, Clinical Research, Personalized Medicine), Disease Area (Cancer, Neurological, Cardiovascular) - Global Forecast to 2028
The global pharmacogenomics market, valued at US$3.3 billion in 2022, stood at US$3.5 billion in 2023 and is projected to advance at a resilient CAGR of 10.6% from 2023 to 2028, culminating in a forecasted valuation of US$5.8 billion by the end of the period. The increasing focus on the translational approach to optimize drug development processes, increasing collaborations and partnerships between key players and research institutes, and rising incidence of cancer are the major driving factors of the pharmacogenomics market.
- Published: February 2024
- Price: $ 4950
- TOC Available:
Records 21 to 30 of 50
